Health industry headlines feature Antares Therapeutics’ strategic $1.9 billion collaboration with Novartis, targeting hard-to-drug cancer therapies. The agreement underscores a trend of high-stakes partnerships aimed at tackling medical challenges previously considered intractable.
The Democratic Republic of Congo faces mounting difficulties as the Ebola outbreak rapidly spreads. Despite response efforts, the World Health Organization reports the highest first-month case total for any Ebola episode, emphasizing the urgency for international intervention and coordinated health strategies.
Meanwhile, the U.S. continues grappling with rising prescription drug prices. While new drug launch prices have seen a decline in 2025, they remain steep, especially for rare disease treatments. This reflects ongoing discussions about drug affordability and pricing policies in the market.
(With inputs from agencies.)